en · de · es · fr · pt
aod-9604-notes.peptides3626.com › News › Background And Research Context — Background and Details

Background And Research Context — Background and Details

By Editorial Desk · published 2025-11-03 · last reviewed 2025-11-19 · News

If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.

Background And Research Context

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Related pages on this site

Regulatory and Analytical Context

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Research and Regulatory Context

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Background from the literature

=== Food === Fumaric acid has been used as a food acidulant since 1946. It is approved for use as a food additive in the EU, USA, Australia, and New Zealand. As a food additive, it is used as an acidity regulator and can be denoted by the E number E297. It is generally used in beverages and baking powders for which requirements are placed on purity. Fumaric acid is used in the making of wheat tortillas as a food preservative and as the acid in leavening. It is generally used as a substitute for tartaric acid and occasionally in place of citric acid, at a rate of 1 g of fumaric acid to every ~1.5 g of citric acid, in order to add sourness, similarly to the way malic acid is used. As well as being a component of some artificial vinegar flavors, such as "Salt and Vinegar" flavored potato chips, it is also used as a coagulant in stove-top pudding mixes. The European Commission Scientific Committee on Animal Nutrition, part of DG Health, found in 2014 that fumaric acid is "practically non-toxic" but high doses are likely nephrotoxic after long-term use.

Protein folding is the physical process by which a protein, after synthesis by a ribosome as a linear chain of amino acids, changes from an unstable random coil into a more ordered three-dimensional structure. This structure permits the protein to become biologically functional or active. The folding of many proteins begins even during the translation of the polypeptide chain. The amino acids interact with each other to produce a well-defined three-dimensional structure, known as the protein's native state. This structure is determined by the amino-acid sequence or primary structure. The correct three-dimensional structure is essential to function, although some parts of functional proteins may remain unfolded, indicating that protein dynamics are important. Failure to fold into a native structure generally produces inactive proteins, but in some instances, misfolded proteins have a modified or toxic functionality. Several neurodegenerative and other diseases are believed to result from the accumulation of amyloid fibrils formed by misfolded proteins, the infectious varieties of which are known as prions. Many allergies are caused by the incorrect folding of some proteins because the immune system does not produce the antibodies for certain protein structures. Denaturation of proteins is a process of transition from a folded to an unfolded state. It happens in cooking, burns, proteinopathies, and other contexts. Residual structure present, if any, in the supposedly unfolded state may form a folding initiation site and guide the subsequent folding reactions.

3 spot in Entrepreneur magazine's 31st Annual Franchise 500, "the first and most comprehensive ranking in the world". This was the 17th year 7-Eleven was named in the top 10. In February 2010, 7-Eleven opened a concept store in DeLand, Florida, across from Stetson University, designed to meet LEED environmental standards. In 2017 they bought 1,110 C-Stores convenience stores from Sunoco in a deal valued at $3.3 billion and in 2024 acquired 204 Stripes convenience stores from Sunoco in a deal valued at $1 billion and finished integrating them in 2026. By 2015, 7-Eleven had over 55,000 stores across the world. In 2020, 7-Eleven announced it would purchase Speedway, 23,000 stores, for $21 billion. In 2021, 7-Eleven rolled out a $70 million ad campaign, their largest investment in advertising in years, doubling their market spending from the previous year. The commercials, directed by Harmony Korine, were to reflect the "evolution" of the chain's store format, drawing attention to, in part, the fact that "this isn't just gas station food, there's real restaurant quality food at 7-Eleven", according to CMO Marissa Jarrantt. On August 19, 2024, it was reported that Alimentation Couche-Tard—owner of competitor Circle K—had made a buyout offer for Seven & i Holdings. Later, on September 6, 2024, Seven & i Holdings rejected this offer as too low and rife with regulatory risk, although a "sweetened offer" might be considered. In October, a revised bid of $47 billion, 22% increase of the previous one, was presented.

Although statistics of the Soviet economy are notoriously unreliable and its economic growth difficult to estimate precisely, by most accounts, the economy continued to expand until the mid-1980s. During the 1950s and 1960s, it had comparatively high growth and was catching up to the West. However, after 1970, the growth, while still positive, steadily declined much more quickly and consistently than in other countries, despite a rapid increase in the capital stock (the rate of capital increase was only surpassed by Japan). Professor of Economic History Bob Allen contends that in the era in which the Soviet economy was publicly owned and planned (1928–1989), the Soviet Union's GDP per capita growth outpaced nearly all other world economies, trailing only Japan, South Korea, and Taiwan. Data shows that Soviet per capita growth expanded by a factor of 5.2, exceeding the growth rates of Western Europe at 4.0, and the US, Canada, Australia, and New Zealand at 3.3. Ultimately, the Soviet model of public ownership proved more effective at raising average incomes during this period than the world's primary industrialized capitalist systems. Scholar Christopher Davidson argued that, during the 1980s, the Reagan administration attempted to weaponize the global energy market against the USSR. At the request of CIA Director William J. Casey, Saudi Arabia flooded the market with oil, dropping the price from $28 to $10 per barrel, and draining Soviet foreign currency reserves. This was later described by a former CIA chief of staff as a "body blow to the Soviets.

Sources: en.wikipedia.org

Further detail

=== Split-&-Pool DNA Encoding === In order to apply combinatorial chemistry for the synthesis of DNA-encoded chemical libraries, a Split-&-Pool approach was pursued. Initially a set of unique DNA-oligonucleotides (n) each containing a specific coding sequence is chemically conjugated to a corresponding set of small organic molecules. Consequently, the oligonucleotide-conjugate compounds are mixed ("Pool") and divided ("Split") into a number of groups (m). In appropriate conditions a second set of building blocks (m) are coupled to the first one and a further oligonucleotide which is coding for the second modification is enzymatically introduced before mixing again. This “split-&-pool” steps can be iterated a number of times (r) increasing at each round the library size in a combinatorial manner (i.e. (n x m)r). Alternatively, peptide nucleic acids have been used to encode libraries prepared by "split-&-pool" method. A benefit of PNA-encoding is that the chemistry can be performed by standard SPPS.

== External links == Histology image: 12_02 at the University of Oklahoma Health Sciences Center - "epiglottis" Histology image: 02901loa – Histology Learning System at Boston University Histology at ucsd.edu Archived 2012-02-05 at the Wayback Machine Anatomy Atlases – Microscopic Anatomy, plate 03.42

Vaginal intracavity brachytherapy (VBT) is used to treat endometrial, vaginal and cervical cancer. An applicator is inserted into the vagina to allow the administration of radiation as close to the site of the cancer as possible. Survival rates increase with VBT when compared to external beam radiation therapy. By using the vagina to place the emitter as close to the cancerous growth as possible, the systemic effects of radiation therapy are reduced and cure rates for vaginal cancer are higher. Research is unclear on whether treating cervical cancer with radiation therapy increases the risk of vaginal cancer.

Sources: en.wikipedia.org

Background from the literature

Calcium (20Ca) has 26 known isotopes, ranging from 35Ca to 60Ca. There are five stable isotopes (40Ca, 42Ca, 43Ca, 44Ca and 46Ca), plus one isotope (48Ca) with such a long half-life that it is for all practical purposes stable. Two isotopes of calcium, 40Ca and 48Ca, are doubly-magic, making them particularly stable nucliides. Calcium also has a cosmogenic isotope, 41Ca, with half-life 99,400 years. Unlike cosmogenic isotopes produced in the air, 41Ca is produced by neutron activation of solid 40Ca in rock and soil. Most of its production is in the upper meter of the soil column, where the cosmogenic neutron flux is still strong enough. Calcium-41 is also produced during stellar nucleosynthesis and decays to 41K, which can be used to understand formation and mixing between solar system reservoirs . The most stable artificial isotopes are 45Ca with half-life 162.61 days and 47Ca with half-life 4.536 days. All other artificial calcium isotopes have half-lives of minutes or less. 40Ca comprises about 97% of natural calcium and is mainly created by nucleosynthesis in stars (alpha process). Like 40Ar, however, some 40Ca is radiogenic, created by radioactive decay of 40K. While K–Ar dating has been used extensively in the geological sciences, the prevalence of 40Ca in nature initially impeded the proliferation of K-Ca dating in early studies, with only a handful of studies in the 20th century.

Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). Naturally occurring AGIs are found in raw plants/herbs such as cinnamon and white mulberry as well as some bacteria. Carbohydrates are normally converted into simple sugars (monosaccharides) by alpha-glucosidase enzymes present on cells lining the intestine, enabling monosaccharides to be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of dietary carbohydrates on blood sugar.

In some Asian cuisines, fish is traditionally fermented with rice to produce lactic acid that preserves the fish. Examples of these dishes include burong isda of the Philippines; narezushi of Japan; and pla ra of Thailand. The same process is also used for shrimp in the Philippines in the dish known as balao-balao.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Network